Who we are. What we do. And why we do it.
Everyman is a campaign that was launched by The Institute of Cancer Research in 1997.
We launched it for 3 main reasons:
The incidence of prostate and testicular cancers was rising dramatically.
A lack of funds meant that too little research had been carried out.
Men were (and many still are) notoriously bad at discussing health matters.
Which added up to one big reason – too many men were dying from prostate and testicular cancer.
Everyman was launched to do 2 things:
To break the taboos surrounding prostate and testicular cancer and raise awareness of them amongst men and women.
To raise funds so that our scientists could carry out research vital to improving the outlook for every man – and so cross out testicular and prostate cancer.
Everyman’s mission is to stamp out testicular and prostate cancer. We can achieve this by making everyone recognise the tell-tale signs, and understand the importance of treating them. By increasing this awareness we also hope to raise money to fund our life-saving research.
A survey conducted by Everyman in 2006 revealed that only 28% of men check their testicles regularly for signs of testicular cancer. A similar survey conducted by Everyman a few years ago also revealed that only 19% of men checked their testicles regularly.
So whilst the number of men checking themselves regularly remains low, there are signs that awareness in men is increasing.
Some Classic Adverts
With your help our scientists have already made a huge difference to men with prostate and testicular cancer.
So far they have:
- * Completely changed the management of prostate cancer by introducing the concept of Active Surveillance. This is now the NICE (National Institute for Health and Clinical Excellence) recommended management of patients with localised non-aggressive prostate cancer.
- * Developed and tested the prostate cancer drug abiraterone, which has shown promising results in early clinical trials and for which we are currently awaiting the definitive results from the final phase of the clinical studies.
- * Over the passed two years, our scientists have identified numerous new genetic variants that increase a man’s risk of developing prostate cancer, leading to a greater understanding of their susceptibility to the disease.
- * Scientist Dramatically improved prostate cancer radiotherapy through the development of conformal and intensity modulated techniques, resulting in both increased cancer control and fewer side effects for patients. We have proved that higher doses of radiotherapy improve prostate cancer remission rates by 30%.
- * Discovery of the first inherited genetic variants for testicular cancer, which can increase a man’s risk of developing testicular cancer by two to three-fold.
- * Identification of three genetic abnormalities that in combination significantly impact how long a prostate cancer patient is likely to survive with the disease. This is one of a number of promising biological markers for prostate cancer that is being investigated as a way to more accurately diagnose the tumour and assess the patients’ response to treatment.
- * Developed the drug carboplatin which has helped lead to a 99% cure rate for testicular cancer and is also widely used in ovarian, lung, head, neck and bladder cancers.
I hope that you will agree that this is a wonderful cause to support, and will help me raise some money for them during the lead up to the London Marathon. Donating couldn’t be easier, click on the badge below to go to my justgiving page and donate online in seconds. Oh and if you can, don’t forget to giftaid! It doesn’t cost you a penny, but it’ll get some extra pennies out of the government to carry on this great research.